EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Immunopathogenesis of bone destruction in multiple myeloma and laboratory diagnostic approaches

Sergey P. Kazakov, Nina S. Leus, Olga V. Denisova, Dmitry V. Reshetnyak, Oleg A. Rukavitsyn

Journal of Clinical Practice · 15.11.2026 · 17 (3) · 67-76

DOI: 10.17816/clinpract707535 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Practice, online erschienen am 15.11.2026. Verfasst von Sergey P. Kazakov und 4 weiteren Autor:innen. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Bone and mineral disorders are among the most frequent and clinically significant manifestations of plasma cell myeloma. Osteodestruction develops as a result of dysregulated bone remodeling, in which resorption predominates over bone formation due to interactions between neoplastic plasma cells and components of the bone and immune microenvironment. Despite advances in therapy, the causes of this imbalance remain the subject of active investigation and are not fully understood. Only a limited number of studies have attempted to systematize the literature on immune mechanisms of osteodestruction in plasma cell myeloma. AIM: To perform a comparative analysis of bone remodeling markers — N-terminal propeptide of type 1 procollagen (P1NP) and β-isomerized C-terminal telopeptides of type 1 collagen (β-crosslaps) — in patients with plasma cell myeloma. METHODS: Serum levels of P1NP and β-crosslaps were measured by electrochemiluminescence immunoassay in 23 patients with plasma cell myeloma and 15 individuals in the control group. RESULTS: P1NP levels were 69% higher in patients with plasma cell myeloma compared to controls (71.50 ng/mL [50.28; 124.00] vs 42.33 ng/mL [25.90; 53.02]; p 0.001). The increase in β-crosslaps levels in plasma cell myeloma patients reached 233% (median 0.80 [0.42; 1.25] vs 0.24 ng/mL [0.17; 0.33]; p 0.001). Receiver operating characteristic (ROC) analysis demonstrated that diagnostic performance indices can be calculated for these markers in distinguishing healthy individuals from plasma cell myeloma patients. The optimal cut-off values were 70.55 ng/mL for P1NP and 0.785 ng/mL for β-crosslaps, with sensitivities of 93% and specificities of 70% and 74%, respectively. The resulting models were statistically significant and showed adequate diagnostic accuracy: the area under the curve (AUC) for P1NP was 0.809 (95% CI 0.667–0.951; p 0.001), and for β-crosslaps was 0.864 (95% CI 0.742–0.986; p 0.001). For rapid laboratory assessment, an osteodestruction index (β-crosslaps/P1NP × 103) was developed and proposed; this index was higher in plasma cell myeloma patients (11.2) than in healthy individuals (5.6). CONCLUSION: The bone remodeling markers β-crosslaps and P1NP provide clinically informative parameters for rapid adjunctive laboratory diagnosis of plasma cell myeloma, while the osteodestruction index allows stratification of plasma cell myeloma patients by the extent of bone tissue damage, which may be important not only for diagnosing complications but also for monitoring antiresorptive therapy.

Zitieren

APA

Kazakov, S. P., Leus, N. S., Denisova, O. V., Reshetnyak, D. V., & Rukavitsyn, O. A. (2026). Immunopathogenesis of bone destruction in multiple myeloma and laboratory diagnostic approaches. Journal of Clinical Practice, 17(3), 67-76. https://doi.org/10.17816/clinpract707535

Vancouver

Kazakov SP, Leus NS, Denisova OV, Reshetnyak DV, Rukavitsyn OA. Immunopathogenesis of bone destruction in multiple myeloma and laboratory diagnostic approaches. Journal of Clinical Practice. 2026;17(3):67-76. doi:10.17816/clinpract707535

BibTeX
@article{Kazakov2026,
  author = {Kazakov, Sergey P. and Leus, Nina S. and Denisova, Olga V. and Reshetnyak, Dmitry V. and Rukavitsyn, Oleg A.},
  title = {Immunopathogenesis of bone destruction in multiple myeloma and laboratory diagnostic approaches},
  journal = {Journal of Clinical Practice},
  year = {2026},
  volume = {17},
  number = {3},
  pages = {67--76},
  doi = {10.17816/clinpract707535}
}
Kostenlos starten →